Medical experts say PCOS should be renamed polyendocrine metabolic ovarian syndrome (PMOS) to capture its wide-ranging effects on metabolic, endocrine, cardiovascular, reproductive, and mental health, with the aim of improving diagnosis, treatment, and research.
A Lancet Diabetes & Endocrinology Commission is exploring the possibility of renaming obesity due to the negative connotations and stigma associated with the term. The current definition and diagnosis of obesity are still riddled with confusion and bias, leading to personal blame and hindering access to clinical care. Experts argue that a new name should better reflect the disease's essential components and characteristics, such as adiposity-based chronic disease (ABCD) or clinical obesity. However, there is a need for greater clarity in defining obesity and distinguishing it as a disease rather than a risk factor. The renaming discussion aims to shape public perceptions, reduce stigma, and improve understanding of the complex relationship between obesity, society, mental health, and food options.
The liver disease community is facing confusion as a global group of liver disease societies voted to change the name of NASH (nonalcoholic steatohepatitis) to MASH (metabolic dysfunction-associated steatohepatitis). However, the new names have gained little traction, with health information sources like WebMD and MayoClinic.org not updating their directories with the new nomenclature. Organizations with NASH in their titles have also not mentioned any upcoming changes, leading to uncertainty in the community.